Skip to main content
. Author manuscript; available in PMC: 2018 Oct 18.
Published in final edited form as: Leukemia. 2018 Apr 17;32(11):2388–2398. doi: 10.1038/s41375-018-0132-y

Figure 2.

Figure 2

A. Progression-free survival (PFS) according to IGHV-MS and ZAP70 expression. B. PFS from the 3-month landmark according to minimal residual disease (MRD) level in bone marrow (BM) after course 3 in the whole patient cohort. C. PFS analysis from the 3-month landmark in all patients who achieved undetectable MRD (U-MRD) status in BM after course 3, according to number of total FCR courses received. D. PFS analysis from the 3-month landmark in mutated-IGHV patients who achieved U-MRD status in BM after course 3, according to number of FCR courses received. E. PFS from the 6-month landmark according to IGHV-MS and MRD positive vs undetectable. F. PFS from the 6-month landmark according to timing of achieving U-MRD status. U-MRD @EOT denotes that the patient was MRD-positive after course 3 and had U-MRD at the end of therapy (EOT).